Literature DB >> 19669865

Comparative effects of cilostazol and aspirin on the impairment of endothelium-dependent cerebral vasodilation caused by acute cigarette smoking in rats.

Hiroki Iida1, Mami Iida, Motoyasu Takenaka, Naokazu Fukuoka, Shuji Dohi.   

Abstract

We previously reported that acute cigarette smoking can cause a dysfunction of endothelium-dependent vasodilation in cerebral vessels, and that a reduction of oxidative stress by agents such as valsartan, fasudil, or apocynin prevented this impairment. Here, our aim was to investigate the comparative effects of two antiplatelet drugs used for stroke-prevention [a phosphodiesterase-3 inhibitor (cilostazol) and a cyclooxygenase inhibitor (aspirin)] on smoking-induced endothelial dysfunction in cerebral arterioles. In Sprague-Dawley rats, we used a closed cranial window preparation to measure the changes in pial vessel diameters induced by topical application of acetylcholine (ACh) following intraperitoneal injection of 0.5% carboxymethyl cellulose sodium salt (CMC; vehicle control for the antiplatelet drugs). After 1-min smoking (1 mg-nicotine cigarette), the arteriolar responses to ACh were reexamined. Finally, after intraperitoneal cilostazol or aspirin (each in 0.5% CMC) pretreatment, we reexamined the vasodilator responses to topical ACh (before and after cigarette smoking). Under control conditions, cerebral arterioles were dose-relatedly dilated by topical ACh (10(-6) and 10(-5 )M). One hour after 1-min smoking, 10(-5 )M ACh (a) constricted cerebral pial arterioles in the control group and in the aspirin-pretreatment group (responses not significantly different from each other), but (b) dilated cerebral pial arteries in the cilostazol pretreatment groups (responses significantly different from those obtained without cilostazol pretreatment). Thus, cilostazol (but not aspirin) may prevent the smoking-induced impairment of endothelium-dependent vasodilation in cerebral pial arterioles.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19669865     DOI: 10.1007/s11239-009-0382-7

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  29 in total

1.  Impairment of nitric oxide synthase-dependent dilatation of cerebral arterioles during infusion of nicotine.

Authors:  Qin Fang; Hong Sun; William G Mayhan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-10-10       Impact factor: 4.733

2.  Effect of cilostazol on impaired vasodilatory response of the brachial artery to ischemia in smokers.

Authors:  Koji Oida; Kiyokazu Ebata; Hideo Kanehara; Jinya Suzuki; Isamu Miyamori
Journal:  J Atheroscler Thromb       Date:  2003       Impact factor: 4.928

3.  Cigarette smoking as a risk factor for stroke. The Framingham Study.

Authors:  P A Wolf; R B D'Agostino; W B Kannel; R Bonita; A J Belanger
Journal:  JAMA       Date:  1988-02-19       Impact factor: 56.272

4.  Angiotensin II type 1 (AT1)-receptor blocker prevents impairment of endothelium-dependent cerebral vasodilation by acute cigarette smoking in rats.

Authors:  Hiroki Iida; Mami Iida; Motoyasu Takenaka; Hisayoshi Fujiwara; Shuji Dohi
Journal:  Life Sci       Date:  2005-10-06       Impact factor: 5.037

5.  Aspirin protected against endothelial damage induced by LDL: role of endogenous NO synthase inhibitors in rats.

Authors:  Sheng Deng; Pan-yue Deng; Jun-lin Jiang; Feng Ye; Jing Yu; Tian-lun Yang; Han-du Deng; Yuan-jian Li
Journal:  Acta Pharmacol Sin       Date:  2004-12       Impact factor: 6.150

6.  Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris.

Authors:  Kouki Watanabe; Shuntaro Ikeda; Jirou Komatsu; Shinji Inaba; Jun Suzuki; Shozo Sueda; Jun-ichi Funada; Masafumi Kitakaze; Michihito Sekiya
Journal:  Am J Cardiol       Date:  2003-07-01       Impact factor: 2.778

7.  Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL.

Authors:  T Heitzer; S Ylä-Herttuala; J Luoma; S Kurz; T Münzel; H Just; M Olschewski; H Drexler
Journal:  Circulation       Date:  1996-04-01       Impact factor: 29.690

8.  Cilostazol suppresses superoxide production and expression of adhesion molecules in human endothelial cells via mediation of cAMP-dependent protein kinase-mediated maxi-K channel activation.

Authors:  So Youn Park; Jeong Hyun Lee; Chi Dae Kim; Won Suk Lee; Won Sun Park; Jin Han; Yong-Geun Kwak; Ki Young Kim; Ki Whan Hong
Journal:  J Pharmacol Exp Ther       Date:  2006-03-17       Impact factor: 4.030

9.  Combination treatment with normobaric hyperoxia and cilostazol protects mice against focal cerebral ischemia-induced neuronal damage better than each treatment alone.

Authors:  Yuko Nonaka; Akihiro Koumura; Kana Hyakkoku; Masamitsu Shimazawa; Shinichi Yoshimura; Toru Iwama; Hideaki Hara
Journal:  J Pharmacol Exp Ther       Date:  2009-03-31       Impact factor: 4.030

10.  The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man.

Authors:  H Akiyama; S Kudo; T Shimizu
Journal:  Arzneimittelforschung       Date:  1985
View more
  3 in total

1.  Preventive effect of varenicline on impairment of endothelial function in cerebral vessels induced by acute smoking in rats.

Authors:  Mami Iida; Hiroki Iida; Motoyasu Takenaka; Kumiko Tanabe; Kenji Iwata
Journal:  J Anesth       Date:  2012-06-29       Impact factor: 2.078

2.  Endothelium-dependent vasodilation in the cerebral arterioles of rats deteriorates during acute hyperglycemia and then is restored by reducing the glucose level.

Authors:  Kazuhiro Kito; Kumiko Tanabe; Koji Sakata; Naokazu Fukuoka; Kiyoshi Nagase; Mami Iida; Hiroki Iida
Journal:  J Anesth       Date:  2018-05-21       Impact factor: 2.078

3.  Effects of topical and intravenous JM-1232(-) infusion on cerebrovascular reactivity in rats.

Authors:  Kenji Iwata; Hiroki Iida; Mami Iida; Naokazu Fukuoka; Kazuhiro Kito; Kumiko Tanabe
Journal:  J Anesth       Date:  2015-04-26       Impact factor: 2.078

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.